ScholarIQanswers from OpenAlex
Ruhrlandklinik
InstitutionResearch output, impact & collaborations
Ruhrlandklinik is a institution indexed in ScholarIQ from OpenAlex.
What is known about Ruhrlandklinik?
ScholarIQrecord summary
Ruhrlandklinik is a research organisation in Essen, DE. OpenAlex records 4,818 works and 224,215 citations for it. 1,144 researchers list it as their most recent affiliation.
How many works does Ruhrlandklinik have?
ScholarIQindexed works
Ruhrlandklinik has 4,818 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Ruhrlandklinik have?
ScholarIQcitation count
Ruhrlandklinik has 224,215 citations in the OpenAlex counts ScholarIQ stores.
How many researchers are at Ruhrlandklinik?
ScholarIQresearcher count
Ruhrlandklinik has 1,144 researchers in the ScholarIQ index.
What is the average h-index at Ruhrlandklinik?
ScholarIQavg h-index
Ruhrlandklinik has an average h-index of 80.5 in OpenAlex.
What is the ROR of Ruhrlandklinik?
ScholarIQror
The ROR for Ruhrlandklinik is on the source record.
What is the OpenAlex record for Ruhrlandklinik?
ScholarIQopenalex
The OpenAlex for Ruhrlandklinik is on the source record.
Who are the most-cited researchers behind Ruhrlandklinik?
ScholarIQtop researchers by citations
1
Ulrich Costabel · Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
804 works52,020 citationsWhat are the most-cited papers on Ruhrlandklinik?
ScholarIQmost cited works
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Julie R. Brahmer, Karen L. Reckamp, Paul Baas, Lucio Crinò, Wilfried Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Płużański, Everett E. Vokes, Esther Holgado, David Waterhouse, Neal Ready, Justin F. Gainor, Osvaldo Arén Frontera, Libor Havel, Martin Steins, Marina Chiara Garassino, Joachim G.J.V. Aerts, Manuel Dómine, Luis Paz‐Ares, Martin Reck, Christine Baudelet, Christopher Harbison, Brian Lestini, David R. Spigel
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Robert Pirker, Jose R. Pereira, Aleksandra Szczęsna, Joachim von Pawel, Maciej Krzakowski, Rodryg Ramlau, Ihor Vynnychenko, Keunchil Park, Chih-Teng Yu, Valentyn Ganul, Jae-Kyung Roh, Emilio Bajetta, Kenneth J. O’Byrne, Filippo de Marinis, Wilfried Eberhardt, Thomas Goddemeier, Michael Emig, U. Gatzemeier
Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)
Leora Horn, David R. Spigel, Everett E. Vokes, Esther Holgado, Neal Ready, Martin Steins, Elena Poddubskaya, Hossein Borghaei, Enriqueta Felip, Luis Paz‐Ares, Adam Płużański, Karen L. Reckamp, Marco Angelo Burgio, Martin Kohlhäeufl, David Waterhouse, Fabrice Barlési, Scott Antonia, Óscar Arrieta, Jérôme Fayette, Lucio Crinò, Naiyer A. Rizvi, Martin Reck, Matthew D. Hellmann, William J. Geese, Ang Li, Anne Blackwood‐Chirchir, Diane Healey, Julie R. Brahmer, Wilfried Eberhardt
Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer
Hossein Borghaei, Scott Gettinger, Everett E. Vokes, Laura Q.M. Chow, Marco Angelo Burgio, Javier de Castro, Adam Płużański, Óscar Arrieta, Osvaldo Arén Frontera, Rita Chiari, Charles Butts, Joanna Wójcik-Tomaszewska, Bruno Coudert, Marina Chiara Garassino, Neal Ready, Enriqueta Felip, M. Alonso Garcìa, David Waterhouse, Manuel Dómine, Fabrice Barlési, Scott Antonia, M Wohlleber, David E. Gerber, Grzegorz Czyżewicz, David R. Spigel, Lucio Crinò, Wilfried Eberhardt, Ang Li, S. Marimuthu, Julie R. Brahmer
Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial
Jürgen Behr, Antje Prasse, Michael Kreuter, Johannes Johow, Klaus F. Rabe, Francesco Bonella, R. Bonnet, Christian Grohé, Matthias Held, Heinrike Wilkens, Peter Hammerl, Dirk Koschel, Stefan Blaas, Hubert Wirtz, Joachim H. Ficker, Wolfgang Neumeister, Nicolas Schönfeld, Martin Claussen, Nikolaus Kneidinger, Marion Frankenberger, Simone Hummler, Nicolas Kahn, Silke Tello, Julia Freise, Tobias Welte, Petra Neuser, Andreas Günther, Jürgen Behr, Michael Kreuter, Johannes Johow, Klaus F. Rabe, Francesco Bonella, R. Bonnet, Christian Grohé, Matthias Held, Heinrike Wilkens, Peter Hammerl, Dirk Koschel, Stefan Blaas, Hubert Wirtz, Joachim H. Ficker, Wolfgang Neumeister, N Schönfeld, Martin Claussen, Nikolaus Kneidinger, Marion Frankenberger, Simone Hummler, Nicolas Kahn, Silke Tello, Julia Freise, Tobias Welte, Petra Neuser, Andreas Günther, Carmen Schade‐Brittinger, Behnaz Aminossadati, Christian Nasemann, Soraya Yahiaoui, Christoph Dupuy Backofen, Maik Hahmann, Michael Wittenberg, Fotis Drakopanagiotakis, Daniel von der Beck, Stefanie Ghofrani, S Heinemann, Ekaterina Krauss, Hella Rethorn, Andrea Koch, Gabriela Leuschner, Sandhya Matthes, Claus Neurohr, Tobias Veit, Katrin Milger, Felix Herth, Julia Benstz, Simone Hummler, Thomas Bahmer, Heike Biller, Benjamin Waschki, Rosa-Marie Apel, Ulrich Costabel, Eva Börner, Thomas Wessendorf, M. Arnrich, Lacramioara Ilie, Alexandra Wald, Hans‐Jürgen Seyfarth, Christian Reinhardt, Atif Cinar, Markus Vogler, Siegfried Matthias Huhn, Jaqueline Richter, U Neff, Torsten Blum, Silvan Vesenbeckh, Christian Boch, Hannes Semper, Andreas Wilke, Michael Pfeifer, Annette Schweda, Angelika Krill
How much of the research on Ruhrlandklinik is open access?
ScholarIQopen access share
75%OPEN ACCESS